At a glance
ClinicalIndex Comparison RecordN/ACompleted· 60 enrolled
Drug / intervention
First line EC/EP+Atezolizumabdrug
Likely dose
First line EC/EP+Atezolizumab 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer Who Treated With Atezolizumab Plus Etoposide and Platinum Based Chemotherapy
In Brief
An observational study evaluating First line EC/EP+Atezolizumab for Extensive Stage Small Cell Lung Cancer. Completed, enrolled 60 participants across 1 site.
Detailed Summary
The purpose of the trial is to detect tumor microenvironment on Extensive Stage Small Cell Lung Cancer with simultaneous liver metastases who Treated with Atezolizumab plus Etoposide and Platinum Based Chemotherapy.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsExtensive Stage Small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartApr 2019
Primary CompletionJul 2021
Study CompletionSep 2021
First PostedSep 2021
TodayJul 2026
First PostedSep 24, 2021
Enrollment StartApr 1, 2019
Primary CompletionJul 1, 2021
Study CompletionSep 1, 2021
TodayJul 1, 2026
Enrollment to primary: 2.3 yearsPosted 4.8 years ago
Interventions
First line EC/EP+Atezolizumabdrug
Etoposide (100mg/㎡) Carboplatin (AUC=4) Atezolizumab(1200mg) ivgtt, every 21 day